BioSpace News Archive

Sapience Therapeutics, Inc. announced today that it will present two late-breaking research posters during the American Association for Cancer Research (AACR) Annual Meeting 2023, taking place April 14-19, 2023, in Orlando, Florida.

Everest Medicines (HKEX 1952.HK, “Everest”, or the “Company”) announced today that the National Medical Products Administration (NMPA) of China has approved its New Drug Application (NDA) for Xerava (eravacycline) for the treatment of complicated intra-abdominal infections (cIAI) in adult patients.

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced publication in the New England Journal of Medicine (NEJM) of results from preclinical studies and a Phase 2 study evaluating the efficacy and safety of inaxaplin (VX-147) on top of standard-of-care in people with focal segmental glomerulosclerosis (FSGS) and two APOL1 variants.

IPA (IMMUNOPRECISE ANTIBODIES LTD.) (the “Company” or “IPA”) (NASDAQ: IPA), an AI-driven biotherapeutic research and technology company, today announced financial results for third quarter fiscal year 2023, which ended January 31, 2023.

Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines, today announced financial results for the fourth quarter ended December 31, 2022 and provided an update on clinical and corporate developments.

MyOme, Inc. will share data from three presentations at the 2023 American College of Medical Genetics and Genomics (ACMG) Annual Clinical Genetics Meeting being held March 14-18, 2023.

Shoreline Biosciences, Inc. (Shoreline) today announced the presentation of preclinical data at the American Association for Cancer Research (AACR) annual meeting taking place in Orlando, FL, from April 14-19, 2023.

Stevanato Group S.p.A. (NYSE: STVN) a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology, and life sciences industries, today announced a collaboration with leading Contract Development and Manufacturing Organisation (CDMO), Recipharm.

Xenetic Biosciences, Inc. today announced that it will participate in the Virtual Investor NETs in Cancer Spotlight Event on Wednesday, March 29, 2023 at 11:00 AM ET.

Braxia Scientific Corp. (CSE: BRAX) (OTC PINK: BRAXF) (FWB: 4960) (“Braxia”, or the “Company”), a medical research and telemedicine company with clinics providing innovative ketamine and psilocybin treatments for depression and related disorders, announces that Irwin Naturals Inc. (“Irwin”) has terminated the non-binding amended and restated letter of intent (“LOI”) for a business combination between Irwin and Braxia (the “Proposed Transaction”).